StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) income statement

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$31.37−1.06 (-3.27%)

Close on Nov 20, 2026Market cap $1.74BP/E –Yield –

See a number that looks wrong?